A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
Clinical trial NCT06212752 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06212752
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-13
- Primary completion
- 2024-11-06
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.